Heart Failure Clinical Trial

Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients

Summary

Patients with congestive heart failure will be assessed for safety and clinical effects of Tolvaptan 30 mg every day versus 15 mg twice a day over a period of 7 days.

View Eligibility Criteria

Eligibility Criteria

History of CHF

Study is for people with:

Heart Failure

Phase:

Phase 2

Estimated Enrollment:

40

Study ID:

NCT00043771

Recruitment Status:

Completed

Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Central Cardiology Medical Clinic
Bakersfield California, , United States
University of California-San Diego
San Diego California, , United States
University of Miami/Jackson Memorial Hospital
Miami Florida, , United States
Medical Research Institute
Slidell Louisiana, , United States
Androscoggin Cardiology Associates
Auburn Maine, , United States
University of Missouri-Kansas City School of Medicine
Kansas City Missouri, , United States
Saint Louis University
St. Louis Missouri, , United States
Cardiology of Oklahoma
Tulsa Oklahoma, , United States
Medical University of South Carolina
Charleston South Carolina, , United States

How clear is this clinincal trial information?

Study is for people with:

Heart Failure

Phase:

Phase 2

Estimated Enrollment:

40

Study ID:

NCT00043771

Recruitment Status:

Completed

Sponsor:


Otsuka Pharmaceutical Development & Commercialization, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider